FierceBiotech ٢٤ فبراير ٢٠٢٦ Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
FierceBiotech ٢٤ فبراير ٢٠٢٦ Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months
FierceBiotech ٢٤ فبراير ٢٠٢٦ ‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
FierceBiotech ٢٣ فبراير ٢٠٢٦ UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FierceBiotech ٢٣ فبراير ٢٠٢٦ Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
FierceBiotech ٢٣ فبراير ٢٠٢٦ MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
FierceBiotech ٢٣ فبراير ٢٠٢٦ iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
FierceBiotech ٢٠ فبراير ٢٠٢٦ Ionis scraps early candidate for Alzheimer’s in people with Down syndrome
FierceBiotech ٢٠ فبراير ٢٠٢٦ Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint